The Food and Drugs Authority (FDA) has cautioned the general public against patronizing a counterfeit anti-malarial drug on the market.
Samples of the counterfeit drug taken from the Northern Region did not contain any of the two active pharmaceutical ingredients stated on the label, hence can be classified as falsified.
“The Food and Drugs Authority (FDA) as part of its market surveillance activities wishes to bring to the attention of health workers and the public, the presence of falsified (counterfeit) antimalarial drug- COMBIART Tablets (Artemether/Lumefantrine 20/120) on our market,” the FDA warned in a statement.
It, therefore, admonished the general public, particularly health workers to be on the lookout for the drug and report to the appropriate authority.
Details of the drug are as follows:
- Batch number: 7225119
- Manufacturing date: 03/2021
- Expiry date: 02/2024
- Manufacturer: Strides Arcolab Ltd.
- NAFDAC Registration: A4-6700
Below is the statement to that effect;